The Federal Trade Commission said the three companies' practices have artificially inflated list prices for insulin.
The Federal Trade Commission has accused three major pharmacy benefit managers of inflating insulin prices, the agency said ...
A new Federal Trade Commission staff report says major social media and video streaming services conducted vast surveillance ...
The Federal Trade Commission alleges that pharmacy benefits managers prioritized high rebates from drug makers for insulin over lower prices for consumers, leading to inflated out-of-pocket costs.
The federal government is suing three big pharmacy benefit managers (PBMs) over a system of drug rebates that regulators say ...
At its annual sellers’ conference, hosted in Seattle this week, Amazon continually told the thousands of independent vendors ...
The loss of accreditation at the University of Kentucky and University of Illinois testing labs played a role in the ...
Health-care company stocks fell as U.S. regulators look to crack down on prices and companies battle over market share of popular drugs. The Federal Trade Commission sued the drug middlemen that ...
FTC sues top PBMs for inflating insulin prices, accusing them of rigging competition and hurting patients. Legal action also includes GPOs.
A group of banks led by Wells Fargo & Co. launched a $1.6 billion delayed-draw term loan to help fund Tempur Sealy ...
The latest health news covers the European Medicines Agency's approval of Novo Nordisk's Wegovy for heart conditions linked ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback